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ABSTRACT
Tay-Sachs disease (TSD, also known as GM2-gangliosidosis) is an incurable
autosomal-recessive neurodegenerative lysosomal storage disease caused by a mutation in
the HEX A gene which codes for the lysosomal enzyme β-hexosaminidase A (Hex A). For
patients with TSD, GM2-gangliosides cannot be properly broken down, and, as a result,
accumulate in their neurons, causing severe neurological complications. Although all past
treatment options have been ineffective, this study set out to reduce the number of GM2gangliosides in cells by increasing Hex A activity using novel pharmacological chaperone
therapy.
Four factors, DMSO, glutamic acid, Pyrimethamine, and a decrease in temperature,
were assessed for their ability to ameliorate Hex A activity in TSD cells and decrease the
GM2-ganglioside buildup in a TSD derived cell line, GM00502. The human kidney
fibroblast cell line contains two of the most common mutations that cause TSD (1278ins4
and 1421+1G→C). The effects of the chaperones outlined in this project have yet to be
tested on a cell line with both of these major mutations. I hypothesized that temperature
reduction, DMSO, glutamic acid, and pyrimethamine would rescue Hex A activity in the
TSD derived human kidney fibroblast cell line GM00502.
A study in cytotoxicity was conducted to find the optimum concentration of DMSO,
glutamic acid, and Pyrimethamine to treat both GM00502 and HEK293 (control) human
kidney fibroblasts. After confirming proposed treatment concentrations were not cytotoxic,
a gradient of three concentrations of each factor was then used in the subsequent testing
phase. Differences in GM2-ganglioside levels were quantified through the use of
LysoTracker DND-26 staining and fluorescence microscopy. GM00502 TSD derived cells
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were shown to contain an increased accumulation of GM2-gangliosides when compared to
the unafflicted HEK293 control cells. After treating GM00502 cells with DMSO, glutamic
acid, Pyrimethamine, and a temperature reduction it was found that all treatments were
able to reduce the overall GM2-ganglioside level. Likewise, each treatment was also able
to further reduce the GM2-ganglioside levels in HEK293 cells. Of the four factors tested,
glutamic acid appeared the most effective in decreasing lysosomal accumulation in both
cell types (p<0.05). Pyrimethamine also appeared to be effective at decreasing lysosomal
accumulation in GM00502 cells (p<0.005).

Keywords:

Tay-Sachs Disease, GM2-gangliosidosis, Lysosomal Storage Disease,

Protein Chaperone Therapy, Pyrimethamine, β-Hexosaminidase A, GM00502, HEK293,
endoplasmic reticulum associated degradation, lysosome, fluorescence microscopy,
LysoTracker DND-26, 1278ins4, 1421+1G→C
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INTRODUCTION
Lysosomal Storage Disorders
Lysosomal Storage Disorders (LSD) are a class of genetic disorders caused by
mutations in the genes that code for one of the approximately 50 degradative enzymes, or
hydrolases, found in the lysosome (Cooper 2000). Mutations that arise in hydrolase genes
ultimately lead to a clinical deficiency in this class of enzyme. Accordingly, the absence
of a single hydrolase will cause an accumulation of the enzyme’s substrate within the cell
(Ferreira and Gahl 2017, Mahuran 1999).
Tay-Sachs Disease
Tay-Sachs disease (TSD, also known as GM2-gangliosidosis) is an autosomalrecessive neurodegenerative LSD caused by a mutation in the HEX A gene which codes
for the lysosomal enzyme β-hexosaminidase A (Hex A) (Solovyena et al. 2017, TriggsRaine et al. 2001). The Hex A enzyme is the only hydrolase that can degrade the
glycosphingolipid GM2-ganglioside (Kolter and Sandhoff 1998). GM2-gangliosides are
used in cell signaling and most commonly found in neuronal cells (Kolter 2012, Mahuran
1999, Palmano et al. 2015). For patients with TSD, GM2-gangliosides cannot be properly
broken down, and, as a result, accumulate in their neurons, causing severe neurological
complications including slow development, seizures, cognitive impairment, immobility,
sight and speech impairments, and death (MacQueen et al. 1998). TSD is most prevalent
in Ashkenazi Jewish populations (Eastern Europeans of Jewish descent) where 1 in 3500
newborns are afflicted with the disease (Petersen et al. 1983, Rozenburg and Pereira
2001). Those afflicted with infantile-onset TSD begin experiencing symptoms around 6
months of age and often die by the age of 5 (Rozenburg and Pereira 2001).
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Pharmacological Chaperone Therapy
Currently, there is no cure for TSD, however, as new technologies have been
developed in the past decade, more treatment options are coming to light. Some emerging
modes of therapy for LSDs include substrate reduction therapy, enzyme replacement
therapy, bone marrow transplantation, and gene therapy using viral vectors.
Unfortunately, all of these proposed treatment options have been unsuccessful against
TSD due to low efficacy and inability to cross the blood-brain barrier (Solovyeva et al.
2018). Although all past treatment options have been ineffective, there are still two novel
techniques that are currently being developed for the treatment of TSD: gene therapy
using the CRISPR-Cas9 system and pharmacological chaperone therapy (PCT).
Here, pharmacological chaperone therapy for TSD was investigated. There are
two different kinds of chaperones which can be employed in pharmacological chaperone
therapy: chemical chaperones and pharmaceutical chaperones. The goal of these
chaperones is to improve folding of the Hex A enzyme and ultimately restore Hex A
activity in order to reduce the amount of GM2 gangliosides in cells. To stop the
accumulation of GM2 gangliosides, only about 10 percent of the normal level of Hex A
enzyme activity is actually needed (Conzelmann and Sandhoff 1984).
Chemical chaperones are low molecular weight compounds used to stabilize
protein conformation (Bernier et al. 2004). Dimethyl Sulfoxide (a versatile solvent)
(Dersh et al. 2016) and glutamic acid (a non-essential amino acid) have both been shown
to improve Hex A activity in in vitro cell culture models of TSD (Suzuki 2014,
Valenzano et al. 2011). While important in in vitro chaperone studies, dimethyl sulfoxide
(DMSO) and glutamic acid are not suitable for clinical use because of their ability to help
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stabilize all misfolded proteins, even those that should be degraded (Valenzano et al.
2011).
Pharmaceutical chaperones (PC) differ from chemical chaperones in their
specificity. While chemical chaperones act by stabilizing all proteins, pharmaceutical
chaperones are uniquely designed to chaperone one specific protein (Suzuki 2014). For
example, Pyrimethamine, the leading PC for treating TSD, specifically stabilizes the Hex
A protein. Pharmaceutical chaperones are, therefore, much better candidates for
therapeutic management of TSD than chemical chaperones. Pyrimethamine is currently
in Phase I and II clinical trials (Clarke et al. 2010). For this reason, pyrimethamine was
selected as the PC for this study.
Chaperone-Independent Hex A Rescue
Previous in vivo research has also demonstrated that lowering mammalian cell
incubation temperature serves as a third method for improving protein folding within
cells. At the molecular level, reduced temperature slows down the cytosolic degradation
step in the endoplasmic reticulum-associated protein degradation (ERAD) system and
gives natural protein folding processes more time to rescue Hex A from unwanted
transportation and degradation (Dersh et al. 2016). In this study, reducing cell incubation
temperature allowed us to investigate whether or not TSD cells can fold and transport
Hex A without the need for chemical or pharmaceutical chaperones. While this treatment
modality cannot be applied to in vivo systems, studying the effects of decreased
temperature remains important in furthering scientific understanding of TSD.
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Experimental Design
TSD results in a 50-fold increase of GM2 ganglioside in neural cells (Pullarkat et
al. 1980). This drastic build-up of lipid-filled lysosomes can be easily seen through
simple staining techniques as seen in a study done by Kohyama et al. in 2016; this group
compared TSD affected tissue samples and unaffected tissue samples. Here, we expected
to see a visible difference between GM00502 and unaffected human kidney fibroblasts.
Differences can be quantified through the use of LysoTracker DND-26 staining and
fluorescent microscopy. This allowed us to examine whether our tested factors decreased
the overall lysosome volume in TSD cells as decreased lysosome volume serves as an
indicator of increased Hex A activity and subsequent drop in GM2 levels (Kohyama
2016). A measured decrease in GM2 gangliosides would show that a decrease in
temperature and our chosen molecular chaperones were capable of ameliorating Hex A
activity in TSD cells (Figure 1).
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Figure 1: Pathology of TSD and intervention of tested chaperone variables. A) In a TSD cell line,
misfolded Hex A is marked for peroxisomal degradation via the endoplasmic reticulum associated
degradation system (ERAD). As a result, GM2 gangliosides accumulate causing a buildup of lipid filled
lysosomes within the cell. B) When a protein chaperone is added, Hex A proteins are able to be transported
properly through the Golgi apparatus and then to the lysosome where it can degrade GM2 gangliosides. As a
result, the accumulation of GM2 ganglioside filled lysosomes is prevented. This model was created using
BioRender.com.

It is important to note that the fate of the mutated Hex A enzymes depends on
their specific mutation. Although all 74 or more mutations in the HEX A gene result in
the same Hex A deficiency, some misfolded Hex A can tend to aggregate, be retained in
the endoplasmic reticulum, or become tagged for cytosolic export and proteasomemediated degradation (Mohamed et al. 2017). Because Hex A fate is mutation-specific, it
is important to know how specific chaperones will perform, especially as researchers
look to treat individuals who are afflicted with those specific mutations (Parenti et al.
2015). Of the 74 mutations for Hex A, three mutations (1278ins4, 1421+1G→C, and
Gly269Ser) account for 98 percent of all TSD cases (Triggs-Raine et al. 2001). The
5

human kidney fibroblast cell line, GM00502, used in this study contained two of these
mutations (1278ins4 and 1421+1G→C) (Ohno and Suzuki 1988, Liu and Zhao 2016,
Triggs-Raine et al. 1990). The effects of the molecular chaperones outlined in this project
have yet to be tested on a cell line with both of these major mutations. This project aimed
to evaluate the efficacy of pyrimethamine on a double mutant cell line. For these reasons,
we chose to research the effects of DMSO, glutamic acid, temperature reduction, and
pyrimethamine on Hex A activity. We hypothesized that temperature reduction, DMSO,
glutamic acid, and pyrimethamine would rescue Hex A activity in the TSD derived
human kidney fibroblast cell line GM00502.
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METHODOLOGY
Summary
TSD derived human kidney fibroblast GM00502 cells and wild-type human
kidney fibroblast HEK293 cells were cultured in Eagle’s Minimum Essential Medium
supplemented with 15% fetal bovine serum and non-essential amino acids at 37℃. Cells
were seeded in 24-well plates and grown to 70% confluence before exposure to treatment
compounds DMSO, glutamic acid, or pyrimethamine for 2.5 hours. Cells treated with a
reduction in temperature were seeded in 24-well plates and grown at 32℃ for the
duration of the experiment. Following exposure to these experimental factors, treatment
media was aspirated, cells were rinsed with PBS, stained with either propidium iodide
(PI) and Hoechst 33342 nuclear stain or Lysotracker DND-26 and Hoechst 33342
solution for ten minutes, and then rinsed. Cells were then imaged by fluorescence
microscopy. Cell cytotoxicity was quantified using Cell Counter Version 1.2.1 (Evan
Dexter, ONU), and Lysotracker fluorescent intensity was quantified using NIH Image J.
Cell Culture
GM00502 TSD derived human kidney fibroblasts were obtained from the Coriell
Institute. HEK293 human kidney fibroblasts were provided by Olivet Nazarene
University. GM00502 and HEK293 fibroblasts were cultured in Eagle’s Minimum
Essential Medium (EMEM) supplemented with 15% fetal bovine serum (FBS), 200mM
L-glutamine, sodium bicarbonate, Penicillin-Streptomycin (antibiotics), and non-essential
amino acids (Sigma). GM00502 cells were used between passages 12 and 17 with media
replacement every 2-3 days. HEK293 cells were used between passages 13 and 19.
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Reagent Preparation
GM00502 and HEK293 cells were treated with complete EMEM supplemented
with their respective amount of their treatment solution. To make each of these treatment
solutions, each chaperone was added to an EMEM stock at the highest tested
concentration and then a series of dilutions were performed to obtain the remaining tested
concentrations as listed in Table 1.
Two stains were used during this experiment. During the cytotoxicity testing a
Hoechst 33342 and propidium iodide (PI) staining solution was prepared by adding 5 µL
x1 Hoechst 33342 in imaging solution and 5 µL of PI to 4990 µL of 1x PBS. During the
variable testing a Lysotracker DND-26 and Hoechst 33342 staining solution was
prepared by adding 5 µL x1 Hoechst 33342 in imaging solution and 800 µL of x20
LysoTracker in imaging solution to 4195 µL of 1x PBS.
Table 1: Chaperone treatment concentrations. Concentrations of tested chaperones in EMEM.
Concentration gradient developed based on published concentrations as denoted by an asterisk (*). – The
concentration of 400 mM glutamic acid caused 100% cell death and was excluded from the testing stage. 1
Dersh et al. 2016. 2 Maegawa et al. 2007.

Chaperone
DMSO1
Glutamic Acid1
Pyrimethamine2

5 mM
50 mM
0.5 µg/mL

Concentration
10 mM
25 mM*
150 mM*
250 mM
1.5 µg/mL*
3 µg/mL

50 mM
–
6 µg/mL

Toxicity Testing
GM00502 and HEK293 cell lines were seeded in 24-well plates and grown to
70% confluence before exposure to treatment compounds DMSO, glutamic acid, or
pyrimethamine for 2.5 hours. Cells treated with a reduction in temperature were seeded in
24-well plates and grown at 32℃ for the duration of the experiment. Each treatment was
conducted in triplicate. A gradient of concentrations was formed from the different wells
according to published concentrations (Table 1).
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After the treatment period, cell culture media was aspirated and the cells were
rinsed with x1 phosphate buffered saline (PBS). Hoechst 33342 and PI staining solution
was then applied for 10 minutes, aspirated, and rinsed with x1 PBS. Hoechst 33342 stains
cell nuclei and is used to quantify total cell count. PI stains only dead cells, allowing cell
cytotoxicity to be quantified. Stained cells were then imaged in x1 PBS with 200x
magnification using fluorescence microscopy (Nikon NIS Element). Cell cytotoxicity
was quantified using Cell Counter Version 1.2.1 (Evan Dexter, ONU).
Variable Testing
GM00502 and HEK293 cell lines were seeded in 24-well plates and grown to
70% confluence before exposure to treatment compounds DMSO, glutamic acid, or
pyrimethamine for 2.5 hours. Cells treated with a reduction in temperature were seeded in
24-well plates and grown at 32℃ for the duration of the experiment. Each treatment was
conducted in triplicate. Three concentrations, low, published, and high were chosen to be
the tested concentrations according to the findings of the cytotoxicity study.
After the treatment period, cell culture media was aspirated and the cells were
rinsed with x1 PBS. LysoTracker DND-26 and Hoechst 33342 staining solution was then
applied for 10 minutes, aspirated, and rinsed with x1 PBS. LysoTracker DND-26 binds to
acidic bodies within the cell, allowing for visualization of lysosomes withing the cell and
an indirect measure of GM2 ganglioside accumulation within cells. Cells were then
imaged in x1 PBS with 200x magnification using fluorescence microscopy (Nikon NIS
Element). LysoTracker fluorescent intensity was quantified using NIH Image J.
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Statistical Analysis
Data are reported as ± SEM. Results were analyzed using ANOVA and were
considered statistically significant at p<0.05.
RESULTS
Cytotoxicity
To accurately assess if our chosen chaperones and reduction in temperature were
able to significantly reduce GM2 ganglioside accumulation within lysosomes, it was
important to first determine if our chosen variables exhibited cytotoxicity against
HEK293 and GM00502 cells. Both HEK293 and GM00502 cells were treated with their
respective chaperone and then assessed for cell count and cytotoxicity using Hoechst
33342 and PI, respectively (Figure 2). DMSO, glutamic acid, Pyrimethamine, and a
reduction in temperature resulted in less than a 3% cell death, on average, for all tested
variables and concentrations, with the exception of 400 mM glutamic acid (Figure 3). A
concentration of 400 mM of glutamic acid, however, caused 100% cell death and was
excluded from the tested variables. Seeing that all tested variables are not cytotoxic, the
three concentrations used for the lysosomal accumulation testing centered around the
previously reported concentrations.

A

B

C

D

Figure 2: Hoechst 33342 and PI staining using fluorescence microscopy. Images A, B, C, and D are
pictures of the same representative sample of GM00502 cells that were treated with 6.0 µg/mL
Pyrimethamine solution and then photographed using fluorescent microscopy. A) Phase contrast. B) Hoechst
33342. C) PI D) Images A, B, and C overlaid to create one final image. Images B and C were used to
determine the total number of cell nuclei (blue) and cell deaths (red).
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A. HEK293 Cytotoxicity

Percent Cell Death

10
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6
4
2
0

Control
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10 mM
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50 mM
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150 mM

250 mM

Glutamic Acid

0.5 µg/ml 1.5 µg/ml 3.0 µg/ml 6.0 µg/ml

32℃

Pyrimethamine

Temperature

B. GM00502 Cytotoxicity

Percent Cell Death

10
8
6
4
2
0

Control

5 mM

10 mM

25 mM

50 mM

50 mM

DMSO

150 mM
Glutamic Acid

250 mM

0.5 µg/ml 1.5 µg/ml 3.0 µg/ml 6.0 µg/ml

32℃

Pyrimethamine

Temperature

Figure 3: Treatment compounds do not significantly impact cell viability. Total cell count and number
of dead cells were quantified using Cell Counter Version 1.2.1. Cell death did not exceed 3%, on average,
for any reported concentrations. A) Cytotoxicity testing of HEK293 cells treated with various concentrations
of DMSO, glutamic acid, pyrimethamine and decreased growth temperature. B) Cytotoxicity of GM00502
cells treated with various concentrations of DMSO, glutamic acid, pyrimethamine and decreased growth
temperature. Values report average cell cytotoxicity ± SEM (n=3).

Lysosome Accumulation
After determining that DMSO, glutamic acid, Pyrimethamine and a decrease in
temperature were not significantly cytotoxic, the efficacy of these variables could be
determined by assessing lysosomal accumulation. To set a baseline for lysosomal
accumulation in both HEK293 and GM00502 cell lines, controls were grown, stained,
and photographed as described (Figure 4).
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A

B

C

D

Figure 4: Phase contrast and lysosomal accumulation controls. Control cells were cultured as described
in the methods. Images were captured at 200x magnification using an inverted fluorescence microscope and
representative images were reported. A) Representative phase contrast of GM00502 human kidney fibroblast
cells. B) Representative phase contrast of HEK293 human kidney fibroblasts. C) Lysosomal accumulation
of untreated GM00502 control cells. D) Lysosomal accumulation of untreated HEK293 control cells.

Average fluorescence intensity (AFI) was quantified using NIH Image J by
averaging the fluorescent intensity of five representative cells and subtracting the average
background fluorescence in five cell-free zones. AFI is reported in arbitrary units (AU). It
was found that the GM00502 AFI was 12.9 ± 1.2 and the HEK293 AFI was 5.2 ± 0.5
(Figure 7). When looking at the control AFI, it can be seen that the TSD derived cell line,
GM00502, has a much higher AFI than the non-mutated fibroblasts. This increase in AFI
is caused by the lysosomal accumulation in the TSD cell line because of Hex A
inactivity. This data empirically verified that the TSD cell line is improperly processing
lipids within the cell. The goal of our treatment variables was to decrease the GM00502
AFI levels to the HEK293 AFI level.
The first treatment observed was temperature (Figure 5). Previous studies have
shown that a reduction in temperature slows the cell’s natural ERAD system and allows
for the proper shuttling of Hex A (Dersh et al. 2016). To evaluate if temperature
reduction would have an effect in a double mutation cell line, HEK293 and GM00502
cells were grown for the entirety of the experiment at 32°C. Lysosomal accumulation was
then assessed using fluorescence microscopy and NIH Image J. Results showed that
GM00502 AFI after temperature reduction was 4.2 ± 1.3 and HEK293 AFI was 2.3 ± 0.1.
12

These results demonstrate that a reduction in temperature was able to significantly reduce
AFI in both cell types (p<0.01, Figure 7). The results demonstrate that temperature
reduction is able to reduce lysosome accumulation in treated GM00502 AFI to a level
below the HEK293 cells at a normal temperature. Additionally, a temperature reduction
was able to even further reduce AFI from 5.2 ± 0.5 to 2.3 ± 0.1 in treated HEK293 cells
(Figure 7).

A

B

C

D

Figure 5: Lysosomal accumulation after a temperature decrease. Both GM00502 and HEK293 cells were
grown at 32°C for the duration of the experiment. Temperature reduction was able to significantly reduce
AFI in both cell types (p<0.01). A) Control GM00502 cells grown at 37°C. B) GM00502 cells grown at
32°C. C) Control HEK293 cells grown at 37°C. D) HEK293 cells grown at 32°C.

The second treatment observed was DMSO (Figure 6A). Dersh et al. previously
reported that DMSO was able to increase Hex A activity in a single mutant cell line
(2016). Here, we sought to evaluate DMSO’s efficacy in a double mutant cell line. Cells
were grown to 70% confluency and then treated with 10, 25, or 50 mM DMSO for 2.5
hours, stained, and imaged using fluorescent microscopy. Average fluorescence intensity
was quantified using NIH Image J. Results showed that when GM00502 cells were
treated with 10, 25, or 50 mM of DMSO their AFIs were 9.4 ± 1.4, 7.3 ± 1.0, and 8.1 ±
0.7, respectively (Figure 7). 10 mM DMSO was not able to significantly decrease
lysosome accumulation. However, both 25 and 50 mM treatments were able to
significantly decrease AFI when compared to untreated control GM00502 cells (p<0.05,
13

Figure 7). Results also showed that when HEK293 cells were treated with 10, 25, or 50
mM of DMSO their AFIs were significantly reduced to 3.53 ± 0.05, 2.7 ± 0.4, and 2.9 ±
0.3, respectively (p<0.05, Figure 7).
The third treatment observed was glutamic acid (Figure 6B). Similar to DMSO,
Dersh et al. previously reported that glutamic acid was also able to increase Hex A
activity in a single mutant cell line (2016). Cells were grown to 70% confluency and then
treated with 50, 150, or 250 mM glutamic acid for 2.5 hours, stained, and imaged using
fluorescent microscopy. Results showed that when GM00502 cells were treated with 50,
150, or 250 mM of glutamic acid their AFIs were 8.9 ± 0.4, 8.7 ± 1.2, and 4.4 ± 1.5,
respectively (Figure 7). 150 mM glutamic acid was not able to significantly decrease
lysosome accumulation. However, both 50 and 250 mM treatments were able to
significantly decrease AFI when compared to untreated control GM00502 cells (p<0.05,
Figure 7). 250 mM glutamic acid provided the greatest reduction in lysosome
accumulation in GM00502 cells. Results also showed that when HEK293 cells were
treated with 50, 150, or 250 mM of glutamic acid their AFIs were significantly reduced to
2.4 ± 0.5, 2.2 ± 0.4, and 1.57 ± 0.02, respectively (p<0.05, Figure 7).
The fourth, and final, treatment observed was Pyrimethamine (Figure 6C).
Maegawa et al. previously reported that Pyrimethamine was able to increase Hex A levels
in two single mutant cell lines (2007). In this study, cells were treated with variable
concentrations of Pyrimethamine for 2.5 hours, stained, and imaged. Results showed that
when double mutant GM00502 cells were treated with 0.5, 1.5, or 3.0 µg/mL
Pyrimethamine their AFIs were significantly reduced to 7.0 ± 0.5, 5.8 ± 0.5, and 6.9 ±
1.3, respectively, when compared to untreated controls (p<0.05, Figure 7). Results also
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showed that when HEK293 cells were treated with 0.5, 1.5, or 3.0 µg/mL of
Pyrimethamine their AFIs were significantly reduced to 2.5 ± 0.5, 2.6 ± 0.4, and 2.1 ±
0.2, respectively (p<0.05, Figure 7).
Of the chemical and pharmaceutical chaperones tested, 250 mM glutamic acid
was the most effective and reduced lysosomal accumulation in GM00502 cells to a level
near that of untreated HEK293 cells. All three concentrations of Pyrimethamine appeared
more effective than DMSO. In HEK293 cells, all chaperones tested reduced lysosomal
accumulation to similar levels. Again, 250 mM glutamic acid was the most effective at
reducing lysosomal accumulation.

GM00502

A: DMSO

10 mmol

25 mmol

50 mmol

Control

10 mmol

25 mmol

50 mmol

HEK293

Control
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GM00502

B: Glutamic Acid

50 mmol

150 mmol

250 mmol

Control

50 mmol

150 mmol

250 mmol

Control

0.5 µg/mL

1.5 µg/mL

3.0 µg/mL

Control

0.5 µg/mL

1.5 µg/mL

3.0 µg/mL

HEK293

Control

HEK293

GM00502

C: Pyrimethamine

Figure 6: Comparison of lysosomal accumulation in chaperone treated GM00502 and HEK293cells.
GM00502 and HEK293 cells were treated with a gradient of DMSO, glutamic acid, and Pyrimethamine
determined by the cytotoxicity study. This figure allows for the visual juxtaposition between treated
GM00502 and HEK293 cell lines. A) Representative pictures of cells treated with a gradient of DMSO. B)
Representative pictures of cells treated with a gradient of glutamic acid. C) Representative pictures of cells
treated with a gradient of Pyrimethamine.
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A. HEK293 Lysosomal Accumulation
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Figure 7: DMSO, glutamic acid, pyrimethamine, and decreased growth temperature ameliorate the
accumulation of GM2 gangliosides. Cells were grown and treated as described in the methods. Cells were
then stained with Lysotracker DND-26 for visualization of lysosomes by fluorescent microscopy. Relative
fluorescent intensity was quantified using NIH Image J software. A) Average fluorescent intensity of
HEK293 cells treated with various concentrations of DMSO, glutamic acid, pyrimethamine, or a temperature
change. B) Average fluorescent intensity of GM00502 cells treated with various concentrations of DMSO,
glutamic acid, pyrimethamine, or a temperature change. Values report average fluorescent intensity ± SEM
(n=3). *p<0.05, **p<0.01, ***p<0.005 compared to HEK293 (A) or GM00502 (B) control cells.
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DISCUSSION
This study set out to ameliorate Hex A activity and decrease the GM2-ganglioside
build up in a double mutant TSD derived cell line, GM00502, using DMSO, glutamic
acid, Pyrimethamine, or a decrease in temperature. TSD is caused by a mutation in the
genetic code for Hex A which prevents the enzyme from being properly transported to
the lysosome. Consequently, GM2-gangliosides accumulate in the lysosomes of TSD
patients and cause severe neurological problems. Protein chaperone therapy aims to find
specific chaperones (either chemical or pharmaceutical) to help stabilize and transport the
functional yet misfolded Hex A enzyme to the lysosome.
Dersh et al. found that the chemical chaperones DMSO and glutamic acid were
effective in increasing Hex A activity in a single Hex A mutant cell line (2016).
Mechanistically, these low molecular weight compounds sequester water molecules,
stabilizing unfolded or misfolded proteins within the cytosol (Valenzano et al. 2011). In
this way, chemical chaperones stabilize misfolded Hex A, allowing the enzyme to be
transported properly. Because these compounds are non-specific, they are capable of
rescuing all misfolded proteins, leading to detrimental mismanagement of the ERAD
system. Because of this, these compounds are not suitable for clinical applications but are
important for understanding the molecular basis of TSD.
Meagawa et al. found that Pyrimethamine is effective in ameliorating Hex A
activity in two, single mutant cell lines (2007). Pyrimethamine was first developed as an
inhibitor to dihydrofolate reductase (DHFR), an enzyme that is structurally similar to Hex
A (Mohamed et al. 2017). Pyrimethamine is capable of crossing the blood-brain barrier,
and is, therefore, a promising pharmaceutical chaperone for Hex A. Mechanistically, it
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readily binds Hex A at the neutral pH within the endoplasmic reticulum, allowing for
proper transport to the lysosome. Pyrimethamine then dissociates upon reaching the
lysosome’s acidic environment, allowing Hex A to properly function. Here, we have
tested the effects of Pyrimethamine on a double mutant cell line and shown that it
restores Hex A activity. In doing so, we have further demonstrated the efficacy of
Pyrimethamine for treating various Hex A mutants.
Three concentrations, centered around the published concentration of each
molecular chaperone, were chosen for the variable testing stage. In HEK293 cells, all
tested variable concentrations significantly decreased lysosomal accumulation. In
GM00502 cells, all tested variables, with the exception of 150 mM glutamic acid and 10
mM DMSO, significantly decreased lysosomal accumulation. 250 mM glutamic acid
appeared the most effective in decreasing lysosomal accumulation in both cell types
(p<0.05). 1.5 ug/mL pyrimethamine achieved the most statistically significant decrease in
lysosomal accumulation in GM00502 cells (p<0.005). This result is in accordance with
Maegowa et al.’s finding that Pyrimethamine is most effective at concentrations between
0.1 and 3.0 µg/mL.
In summary, we found that the pharmacological chaperone with the greatest
clinical potential, Pyrimethamine, was a significantly effective treatment for decreasing
lysosomal build up in the double mutant, GM00502 cells. Our in vitro results support
further clinical trials of this compound. Additionally, novel compounds should be tested
to find novel molecular chaperone treatment options for TSD.
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